HTG Molecular Diagnostics, provider of molecular technology solutions, announced the availability of the qFix Arrays for gene expression analysis at the annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida. The research use only (RUO) arrays are pre-configured and validated to enable researchers to quickly and efficiently conduct translational medicine and clinical validation studies.
HTG provides molecular testing capabilities for clinical researchers, pharmaceutical clinical development and clinical testing laboratories. The Company’s molecular technology solutions include multiplexed and multiparameter assays for precise, accurate, and cost-effective detection of mRNA, miRNA, siRNA, gene fusions, slice variants, and single nucleotide variants (SNVs). The platform allows scientists to test any sample, including formalin fixed paraffin embedded (FFPE) tissue samples while avoiding extraction and target amplification.
“Due to the inherent variance in samples, researchers need the confidence and predictability of a set of vetted control genes to conduct quantitative molecular analysis,” said TJ Johnson, chief executive officer, HTG Molecular Diagnostics. “HTG’s new arrays are designed to help researchers glean both meaningful and accurate results. Our goal is to provide state-of-the-art testing solutions to help our customers shorten their validation studies. In drug discovery and development as well as academic translational medicine, the qFix Arrays offer a rapid gene expression analysis platform that’s reliable and easy to use.”
